

Stephen Spellman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5875472/publications.pdf>

Version: 2024-02-01

110
papers

6,108
citations

87888

38
h-index

71685

76
g-index

112
all docs

112
docs citations

112
times ranked

5732
citing authors

#	ARTICLE	IF	CITATIONS
1	Cryopreservation of Allogeneic Hematopoietic Cell Grafts Did Not Adversely Impact Early Post-Transplant Survival during the First Six Months of the COVID-19 Pandemic. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S75-S76.	1.2	0
2	Unrelated Donor Registry HLA Match Likelihoods in the Mismatched Setting. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S261-S262.	1.2	1
3	Race and Survival in Unrelated Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 357.e1-357.e6.	1.2	9
4	Natural Killer Cell Alloreactivity Predicted By Killer Cell Immunoglobulin-Like Receptor Ligand Mismatch Does Not Impact Engraftment in Umbilical Cord Blood and Haploidentical Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 483.e1-483.e7.	1.2	2
5	Association of Chronic Graft-versus-Host Disease with Late Effects following Allogeneic Hematopoietic Cell Transplantation for Children with Hematologic Malignancy. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 712.e1-712.e8.	1.2	3
6	Genome-Wide Association Analyses Identify Variants in IRF4 Associated With Acute Myeloid Leukemia and Myelodysplastic Syndrome Susceptibility. <i>Frontiers in Genetics</i> , 2021, 12, 554948.	2.3	8
7	National Marrow Donor Programâ€“Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide. <i>Journal of Clinical Oncology</i> , 2021, 39, 1971-1982.	1.6	90
8	Following Transplantation for Acute Myelogenous Leukemia, Donor <i><i>KIR Cen B02</i></i> Better Protects against Relapse than <i><i>KIR Cen B01</i></i> . <i>Journal of Immunology</i> , 2021, 206, 3064-3072.	0.8	8
9	Blueprint for the discovery of biomarkers of toxicity and efficacy for CAR T cells and T-cell engagers. <i>Blood Advances</i> , 2021, 5, 2519-2522.	5.2	10
10	Genetics of HLA Peptide Presentation and Impact on Outcomes in HLA-Matched Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 591-599.	1.2	4
11	Impact of Previously Unrecognized HLA Mismatches Using Ultrahigh Resolution Typing in Unrelated Donor Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2021, 39, 2397-2409.	1.6	19
12	Role of HLA-B exon 1 in graft-versus-host disease after unrelated haemopoietic cell transplantation: a retrospective cohort study. <i>Lancet Haematology</i> , 2020, 7, e50-e60.	4.6	53
13	HLA-B Leader and Survivorship after HLA-Mismatched Unrelated Donor Transplantation. <i>Blood</i> , 2020, 136, 362-369.	1.4	20
14	Analysis of the Whole CDR3 T Cell Receptor Repertoire after Hematopoietic Stem Cell Transplantation in 2 Clinical Cohorts. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1050-1070.	2.0	5
15	<i><i>KIR B</i></i> donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation. <i>Blood Advances</i> , 2020, 4, 740-754.	5.2	42
16	KIR Donor Selection: Feasibility in Identifying better Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e28-e32.	2.0	28
17	Regarding â€œRecipients Receiving Better HLA-Matched Hematopoietic Cell Transplantation Grafts, Uncovered by a Novel HLA Typing Method, Have Superior Survival: A Retrospective Studyâ€•. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e268-e269.	2.0	7
18	Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1875-1883.	2.0	14

#	ARTICLE	IF	CITATIONS
19	A cure-rate model for Q&learning: Estimating an adaptive immunosuppressant treatment strategy for allogeneic hematopoietic cell transplant patients. <i>Biometrical Journal</i> , 2019, 61, 442-453.	1.0	5
20	HLA mismatches that are identical for the antigen recognition domain are less immunogenic. <i>Bone Marrow Transplantation</i> , 2018, 53, 729-740.	2.4	5
21	Current Knowledge and Practice of Pediatric Providers in Umbilical Cord Blood Banking. <i>Clinical Pediatrics</i> , 2018, 57, 161-167.	0.8	4
22	Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 521-528.	2.0	34
23	Chromosome Y& encoded antigens associate with acute graft-versus-host disease in sex-mismatched stem cell transplant. <i>Blood Advances</i> , 2018, 2, 2419-2429.	5.2	11
24	Upper gastrointestinal acute graft-versus-host disease adds minimal prognostic value in isolation or with other graft-versus-host disease symptoms as currently diagnosed and treated. <i>Haematologica</i> , 2018, 103, 1708-1719.	3.5	8
25	Optimal Practices in Unrelated Donor Cord Blood Transplantation for Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 882-896.	2.0	117
26	Tools for the Precision Medicine Era: How to Develop Highly Personalized Treatment Recommendations From Cohort and Registry Data Using Q-Learning. <i>American Journal of Epidemiology</i> , 2017, 186, 160-172.	3.4	40
27	Functional Genetic Variants on 14Q32 Associate with Death Due to Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Within One Year after HLA-Matched Unrelated Donor Blood and Marrow Transplantation (DISCOVeRY-BMT Study). <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S99-S100.	2.0	0
28	Novel Genetic Variants Associated with Death Due to Acute Lymphoblastic Leukemia Within One Year after HLA-Matched Unrelated Donor Blood and Marrow Transplantation (DISCOVeRY-BMT Study). <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S18.	2.0	6
29	Improved survival after acute graft-versus-host disease diagnosis in the modern era. <i>Haematologica</i> , 2017, 102, 958-966.	3.5	79
30	Replication and validation of genetic polymorphisms associated with survival after allogeneic blood or marrow transplant. <i>Blood</i> , 2017, 130, 1585-1596.	1.4	45
31	Allele-level HLA matching for umbilical cord blood transplantation for non-malignant diseases in children: a retrospective analysis. <i>Lancet Haematology</i> , 2017, 4, e325-e333.	4.6	72
32	Fast and accurate HLA typing from short-read next-generation sequence data with xHLA. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 8059-8064.	7.1	118
33	Recipient HLA-C Haplotypes and microRNA 148a/b Binding Sites Have No Impact on Allogeneic Hematopoietic Cell Transplantation Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 153-160.	2.0	12
34	Genetic association with B-cell acute lymphoblastic leukemia in allogeneic transplant patients differs by age and sex. <i>Blood Advances</i> , 2017, 1, 1717-1728.	5.2	15
35	KIR3DL1/HLA-B Subtypes Govern Acute Myelogenous Leukemia Relapse After Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2017, 35, 2268-2278.	1.6	109
36	The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes. <i>Haematologica</i> , 2016, 101, 1426-1433.	3.5	53

#	ARTICLE	IF	CITATIONS
37	Genome-Wide Association Study of Cause-Specific Transplant-Related Mortality (TRM) after HLA-Matched Unrelated Donor Allogeneic BMT for Acute Leukemia or Myelodysplastic Syndrome Demonstrates Unique, Non-Overlapping Genetic Associations (Discovery-BMT). <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S74-S75.	2.0	0
38	Functional Single Nucleotide Polymorphisms (SNPs) in the Major Histocompatibility Complex (MHC) Class II Region Are Associated with Overall Survival (OS) after HLA Matched Unrelated Donor BMT: Results from the Discovery-BMT Study. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S72-S73.	2.0	3
39	Killer Cell Immunoglobulin-Like Receptorâ€“Ligand Matching and Outcomes after Unrelated Cord Blood Transplantation in Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1284-1289.	2.0	28
40	The limitations of qPCR telomere length measurement in diagnosing dyskeratosis congenita. <i>Molecular Genetics & Genomic Medicine</i> , 2016, 4, 475-479.	1.2	20
41	OR18 Full gene sequencing reveals very limited variation in the regions outside of the antigen recognition domains (ARD) of 360 unrelated hematopoietic stem cell transplant donor-recipient pairs matched for 10/10 at high resolution. <i>Human Immunology</i> , 2016, 77, 15.	2.4	0
42	OR43 Frequency of HLA DPA1 and DPB1 mismatching in a population of 1199 pairs of presumed HLA identical sibling transplant pairs. <i>Human Immunology</i> , 2016, 77, 37.	2.4	0
43	Analytical Validation of a Relative Average Telomere Length Assay in a Donor Population for Hematopoietic Stem Cell Transplant (HCT). <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S306.	2.0	0
44	Role for Pediatric Providers in Promotion of Umbilical Cord Blood Banking - Potential Untapped Resource?. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S419-S420.	2.0	0
45	Recovery of Unrelated Donors of Peripheral Blood Stem Cells versus Recovery of Unrelated Donors of Bone Marrow: A Prespecified Analysis from the Phase III Blood and Marrow Transplant Clinical Trials Network Protocol 0201. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1108-1116.	2.0	26
46	Analysis of a Genetic Polymorphism in the Costimulatory Molecule TNFSF4 with Hematopoietic Stem Cell Transplant Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 27-36.	2.0	9
47	Estimating KIR Haplotype Frequencies on a Cohort of 10,000 Individuals: A Comprehensive Study on Population Variations, Typing Resolutions, and Reference Haplotypes. <i>PLoS ONE</i> , 2016, 11, e0163973.	2.5	26
48	MHC Class I Chain-Related Gene a (MICA) Donor-Recipient Mismatches and MICA-129 Polymorphism in Unrelated Donor Hematopoietic Stem Cell Transplants (HSCT) for Hematological Malignancies: A CIBMTR Study. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S156-S157.	2.0	0
49	Progress toward curing HIV infection with hematopoietic cell transplantation. <i>Stem Cells and Cloning: Advances and Applications</i> , 2015, 8, 109.	2.3	8
50	Impact of KIR and HLA Genotypes on Outcomes after Reduced-Intensity Conditioning Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1589-1596.	2.0	37
51	HLA Mismatch Is Associated with Worse Outcomes after Unrelated Donor Reduced-Intensity Conditioning Hematopoietic Cell Transplantation: An Analysis from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1783-1789.	2.0	83
52	Establishment of Definitions and Review Process for Consistent Adjudication of Cause-specific Mortality after Allogeneic Unrelated-donor Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1679-1686.	2.0	37
53	Toll-Like Receptor Polymorphisms in Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 259-265.	2.0	11
54	Donor Killer Cell Ig-like Receptor B Haplotypes, Recipient HLA-C1, and HLA-C Mismatch Enhance the Clinical Benefit of Unrelated Transplantation for Acute Myelogenous Leukemia. <i>Journal of Immunology</i> , 2014, 192, 4592-4600.	0.8	139

#	ARTICLE	IF	CITATIONS
55	HLA Match Likelihoods for Hematopoietic Stem-Cell Grafts in the U.S. Registry. <i>New England Journal of Medicine</i> , 2014, 371, 339-348.	27.0	861
56	Cytotoxic T-Lymphocyte Antigen-4 Single Nucleotide Polymorphisms Are Not Associated with Outcomes after Unrelated Donor Transplantation: A Center for International Blood and Marrow Transplant Research Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 900-903.	2.0	10
57	CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. <i>Blood</i> , 2014, 123, 3016-3026.	1.4	220
58	Sensitization to HY-Antigen in Female Donors Was Not Associated with the Post-Transplant HY-IgG Development Nor Clinical Outcomes in Sex-Mismatched Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S54-S55.	2.0	0
59	Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy. <i>Blood</i> , 2014, 123, 133-140.	1.4	239
60	Significance of Ethnicity in the Risk of Acute Graft-versus-Host Disease and Leukemia Relapse after Unrelated Donor Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1197-1203.	2.0	63
61	Hematopoietic Cell Transplantation with Cord Blood for Cure of HIV Infections. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 393-397.	2.0	32
62	Influence Of Killer Immunoglobulin-Like Receptor (KIR) and HLA Genotypes On Outcomes After Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation For Patients With AML and MDS: A Report From The Center For International Blood and Marrow Transplant Research Immunobiology Working Committee. <i>Blood</i> , 2013, 122, 159-159.	1.4	2
63	Trends In Incidence, Presentation, and Outcomes Of Chronic Graft-Versus-Host Disease In Allogeneic Transplantation- Report From The Center For International Blood and Marrow Transplant Research. <i>Blood</i> , 2013, 122, 3309-3309.	1.4	1
64	HLA-Mismatch Is Associated With Worse Outcomes After Unrelated Donor Reduced Intensity Conditioning Hematopoietic Cell Transplantation: A Cibmtr Analysis. <i>Blood</i> , 2013, 122, 547-547.	1.4	3
65	Recipient HLA-C1 Enhances The Clinical Advantage Of Killer-Cell Immunoglobulin-Like Receptor B haplotype Donors In Myeloablative Unrelated Transplantation For Acute Myelogenous Leukemia. <i>Blood</i> , 2013, 122, 549-549.	1.4	0
66	HLA-C*01:02-Dependent Prevention of Leukemia Relapse by Donor Activating KIR2DS1. <i>New England Journal of Medicine</i> , 2012, 367, 805-816.	27.0	398
67	Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study. <i>Lancet Oncology</i> , The, 2012, 13, 366-374.	10.7	289
68	Unrelated Donor Cord Blood Transplantation for Children with Severe Sickle Cell Disease: Results of One Cohort from the Phase II Study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1265-1272.	2.0	181
69	Scoring HLA Class I Mismatches by HistoCheck Does Not Predict Clinical Outcome in Unrelated Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 739-746.	2.0	34
70	Effect of HLA-Matching Recipients to Donor Noninherited Maternal Antigens on Outcomes after Mismatched Umbilical Cord Blood Transplantation for Hematologic Malignancy. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1890-1896.	2.0	82
71	A combined DPA1*04:01 amino acid epitope is the primary unit of selection on the HLA-DP heterodimer. <i>Immunogenetics</i> , 2012, 64, 559-569.	2.4	47
72	Allele-Level Haplotype Frequencies and Pairwise Linkage Disequilibrium for 14 KIR Loci in 506 European-American Individuals. <i>PLoS ONE</i> , 2012, 7, e47491.	2.5	85

#	ARTICLE	IF	CITATIONS
73	Amino Acid Substitution At Peptide-Binding Pockets of HLA Class I Molecules Adversely Impacts Hematopoietic Cell Transplantation Outcomes. <i>Blood</i> , 2012, 120, 467-467.	1.4	0
74	Donor KIR3DL1 and HLA-B Allotypes Control Leukemia Relapse After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2012, 120, 349-349.	1.4	3
75	Identification of High Risk HLA Class I Amino Acid Substitutions in Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2012, 120, 3050-3050.	1.4	0
76	Guidelines for the development and validation of new potency assays for the evaluation of umbilical cord blood. <i>Cytotherapy</i> , 2011, 13, 848-855.	0.7	31
77	HLA-C Antigen Mismatch Is Associated with Worse Outcome in Unrelated Donor Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 885-892.	2.0	196
78	Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. <i>Blood</i> , 2011, 117, 6714-6720.	1.4	128
79	Effect of donorâ€œrecipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis. <i>Lancet Oncology</i> , The, 2011, 12, 1214-1221.	10.7	192
80	HLA mismatches and hematopoietic cell transplantation: structural simulations assess the impact of changes in pep-tide binding specificity on transplant outcome. <i>Immunome Research</i> , 2011, 7, 4.	0.1	9
81	HLA DR15 Antigen Status Does Not Impact Graft-Versus-Host Disease or Disease-Free Survival in HLA-Matched Sibling Transplantation for Hematologic Malignancies. <i>Blood</i> , 2011, 118, 3094-3094.	1.4	0
82	Donor activating KIR3DS1 is associated with decreased acute GVHD in unrelated allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2010, 115, 3162-3165.	1.4	99
83	Donor and recipient chemokine receptor CCR5 genotype is associated with survival after bone marrow transplantation. <i>Blood</i> , 2010, 115, 2311-2318.	1.4	32
84	Insufficient evidence for association of NOD2/CARD15 or other inflammatory bowel diseaseâ€œassociated markers on GVHD incidence or other adverse outcomes in T-replete, unrelated donor transplantation. <i>Blood</i> , 2010, 115, 3625-3631.	1.4	40
85	The detection of donor-directed, HLA-specific alloantibodies in recipients of unrelated hematopoietic cell transplantation is predictive of graft failure. <i>Blood</i> , 2010, 115, 2704-2708.	1.4	249
86	The Effect of the Composition of Unrelated Donor Bone Marrow and Peripheral Blood Progenitor Cell Grafts on Transplantation Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 253-262.	2.0	28
87	Permissive HLA-DPB1 Mismatching Compared to a Non-Permissive Mismatching Significantly Improves Overall Survival Following Allogeneic Transplantation In Patients with Both 10/10 and 9/10 Matched Unrelated Donors. <i>Blood</i> , 2010, 116, 227-227.	1.4	3
88	Chronic Graft-Versus-Host Disease Risk Score: A CIBMTR Analysis. <i>Blood</i> , 2010, 116, 898-898.	1.4	0
89	Risk Factors for Major Transplant Related Outcomes In Pediatric Patients with Chronic Graft-Versus-Host Disease. <i>Blood</i> , 2010, 116, 211-211.	1.4	0
90	Prior rituximab correlates with less acute graftâ€œversusâ€œhost disease and better survival in Bâ€œcell lymphoma patients who received allogeneic peripheral blood stem cell transplantation. <i>British Journal of Haematology</i> , 2009, 145, 816-824.	2.5	66

#	ARTICLE	IF	CITATIONS
91	Effects of Mismatching for Minor Histocompatibility Antigens on Clinical Outcomes in HLA-Matched, Unrelated Hematopoietic Stem Cell Transplants. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 856-863.	2.0	47
92	Sibling versus Unrelated Donor Allogeneic Hematopoietic Cell Transplantation for Chronic Myelogenous Leukemia: Refined HLA Matching Reveals More Graft-versus-Host Disease but not Less Relapse. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1475-1478.	2.0	39
93	Race and Socioeconomic Status Influence Outcomes of Unrelated Donor Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1543-1554.	2.0	135
94	The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. <i>Blood</i> , 2009, 113, 3110-3118.	1.4	147
95	Selection of Donors with Favorable KIR B Genotypes for Unrelated Hematopoietic Cell Transplantation Results in Superior Relapse Protection and Better Relapse-Free Survival for Patients with AML. <i>Blood</i> , 2009, 114, 665-665.	1.4	1
96	Classification of HLA-Matching for Retrospective Analysis of Unrelated Donor Transplantation: Revised Definitions to Predict Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 748-758.	2.0	186
97	Advances in the Selection of HLA-Compatible Donors: Refinements in HLA Typing and Matching over the First 20 Years of the National Marrow Donor Program Registry. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 37-44.	2.0	91
98	National Marrow Donor Program HLA Matching Guidelines for Unrelated Adult Donor Hematopoietic Cell Transplants. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 45-53.	2.0	132
99	HLAMatchmaker-Defined Triplet Matching Is Not Associated with Better Survival Rates of Patients with Class I HLA Allele Mismatched Hematopoietic Cell Transplants from Unrelated Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1064-1071.	2.0	40
100	Unrelated Donor Hematopoietic Cell Transplantation: Factors Associated with a Better HLA Match. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1334-1340.	2.0	46

101

#	ARTICLE	IF	CITATIONS
109	High Resolution HLA Matched Unrelated Donor Versus HLA Identical Sibling Transplantation for Chronic Phase CML. Blood, 2007, 110, 171-171.	1.4	12
110	Single or Multiple HLA-A, B, C or DRB1 Mismatches Limit Success of Unrelated Donor Bone Marrow Transplantation.. Blood, 2006, 108, 172-172.	1.4	4